Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.

[1]  J. Eckel-Passow,et al.  The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years. , 2011, Leukemia research.

[2]  M. Farrar,et al.  Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. , 2010, Blood.

[3]  Thomas S. Lin,et al.  Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Moreau,et al.  Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin‐2 stimulation: A Belgian multicentric study , 2009, Genes, chromosomes & cancer.

[5]  R. Herbrecht,et al.  Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities , 2009, Leukemia.

[6]  A. Jukkola-Vuorinen,et al.  Toll-Like Receptor 9 Mediates CpG Oligonucleotide–Induced Cellular Invasion , 2008, Molecular Cancer Research.

[7]  T. Haferlach,et al.  Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. , 2006, Blood.

[8]  T. Shanafelt,et al.  Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. , 2006, Cancer genetics and cytogenetics.

[9]  K. Reddy,et al.  Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel , 2006, British journal of haematology.

[10]  M. Caligiuri,et al.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Mayr,et al.  Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. , 2006, Blood.

[12]  Lisa L. Smith,et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.

[13]  W. Hiddemann,et al.  CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B‐cell chronic lymphocytic leukaemia cells , 2002, British journal of haematology.

[14]  S. Akira,et al.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[16]  C. Peschel,et al.  Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. , 2000, Experimental hematology.

[17]  C. Peschel,et al.  Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. , 2000, Blood.

[18]  L. Manzel,et al.  CpG‐oligodeoxynucleotide‐resistant variant of WEHI 231 cells , 1999, Journal of leukocyte biology.

[19]  R. Buhmann,et al.  CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. , 1999, Blood.

[20]  K. Döhner,et al.  Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia , 1998, Annals of Hematology.

[21]  P. Andersen,et al.  In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. , 1997, Leukemia research.

[22]  J. Dierlamm,et al.  Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. , 1997, Cancer genetics and cytogenetics.

[23]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.

[24]  Golder N Wilson,et al.  The frequency of aneuploidy in cultured lymphocytes is correlated with age and gender but not with reproductive history. , 1990, American journal of human genetics.

[25]  G. Gahrton,et al.  Abnormal/normal metaphase ratio and prognosis in chronic B-lymphocytic leukemia. , 1985, Cancer genetics and cytogenetics.

[26]  L. Zech,et al.  Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. , 1980, Blood.

[27]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[28]  P. Nowell,et al.  Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients. , 1991, Leukemia & lymphoma.

[29]  L. Zech,et al.  Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. , 1985, Blood.

[30]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .